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Introduction
Vulvovaginal candidosis (VVC) is one of the most com-
mon infections of the female genital tract. Almost 75% of
all women suffer from VVC at least once per lifetime [1-3].
In around 10% of these cases, women are affected by re-
current episodes of vaginal candida infection [4-6]. Most
often the infection is caused by Candida (C.) albicans in
about 85% of cases, followed by C. glabrata (4-5%), and
other subspecies [1, 4].
Several factors predisposing for acute VVC are identi-
fied. Well known are immunosuppressive diseases, en-
docrine diseases (most importantly diabetes) and antibiotic
therapy which causes an imbalance of the vaginal micro-
flora [1, 2, 5-7]. Furthermore, there is evidence that an al-
lergic predisposition and association with atopy might
represent additional causative factors [8-10]. 
The vaginal defence mechanisms seem to act largely in-
dependently from the systemic immune system [11] which
is supported by the observation that women suffering from
recurrent VVC appear not to have higher susceptibility for
candidosis of other mucous membranes as in the mouth or
esophagus [12].
The cell-mediated immunity plays an important role in
the local vaginal defence mechanisms against candida in-
fections. T-lymphocytes represent major components of this
immune response. They are activated by the presentation
of antigens and different interaction between immune cells.
This process is modulated by the release of cytokines.
Aside of the well known subtypes Th-1 and Th-2 T-
helper cells, a third subtype, the Th-17-helper cells (Th17)
was identified a few years ago. It is characterized by the
production of IL-17 [13]. An increased production of Th17
was observed to be associated with several chronic inflam-
matory and autoimmune diseases [14, 15]. However, Th17
also seem to have protective capacities. They appear to pro-
vide protection against pathogens which are not sufficiently
covered by Th1 or Th2-cells [16]. C. albicans was de-
scribed to be one of these pathogens which mainly induced
a Th17 response [17, 18]. In humans, IL-23, among others,
induces Th17 differentiation from naive T cells [19]. The
Th17 mediated immune response seems to be important es-
pecially in mucous membranes and epithelia [20].
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Summary
Purpose of the investigation: Vulvovaginal candidosis (VVC) is a common vaginal infection affecting almost 75% of all women
once per lifetime. Vaginal associated immunity is important in the protection against VVC. The purpose of this study was to evaluate a
potential role of IL-23, IFN-α, and IFN-β in the local immune response against VVC. Materials and Methods: The study included 202
non-pregnant women; 71 patients with clinical symptoms of VVC and 131 asymptomatic patients served as control. IL-23, IFN-α, and
IFN-β were measured in the vaginal fluid by ELISA. Microbiological cultures were used for Candida detection. Results: C. albicans was
detected in 67.6% of patients, C. glabrata in 21.1% of patients, and 5.6% were infected with C. krusei or coinfected with C. albicans
and C. krusei. Levels of IL-23 (p < 0.001) and IFN-β (p < 0.017) were significantly lower in the VVC group. IFN-α was elevated in the
VVC group compared to the asymptomatic patients (p < 0.001). Conclusion: IL-23 and IFN-β seem to play a protective role against
VVC. Decreased levels in VVC patients suggest a compromised local immune response at the time of occurrence of symptoms. In con-
trast, IFN-α seems to be released once the infection has occurred. These cytokines may be prospective targets in the treatment and pre-
vention of primary and recurrent vaginal infections with Candida species.
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IFN-α and IFN-β are substantial components of the de-
fence mechanisms against viruses [21]. Their role in the de-
fence against other pathogens is explored to a lesser extent.
However, there is evidence that IFN-α is involved in the
defence against C. albicans [22].
Since antimycotic treatment does not always result in suf-
ficient relief of VVC symptoms and the infection often
reappears, there is reason to believe that underlying defects
of the local immune system may be responsible. The pur-
pose of this study was to evaluate whether an immunosup-
pression is already detectable in patients with symptomatic
non- chronic VVC. Therefore, a potential role of the cy-
tokines IL-23, IFN-α, and IFN-β was evaluated.
Materials and Methods
A total of 202 non pregnant patients were included in the pres-
ent analysis. The test group consisted of 71 patients suffering from
microbiologically confirmed VVC. 131 patients presenting for
their gynecologic routine check up asymptomatic of VVC symp-
toms were included in the control group. All patients were inter-
viewed regarding contraception, antibiotic use, history of STD’s,
and vaginal infections.
Exclusion criteria were as follows: pregnancy, use of antibiotics
or antimycotics within the past 30 days, autoimmune or endocrine
disorders, and no informed consent. Vaginal fluid was obtained
and tested for the presence of candida species and the cytokines
IL-23, IFN-α, and IFN-β.
Candida detection by culture 
Vaginal secretion was inoculated on sabouraud agar and incu-
bated for 48 hours at 37°C. Specification for candida species was
done by inoculation of CHROM agar . CHROM agar allows se-
lective isolation of yeasts and simultaneous identification of
colonies of C. albicans, C. glabrata, C. krusei, and C. tropicalis. A
distinctive colour of the colony after incubation for 24 hours at
37°C allowed the differentiation of each subtype [23].
Measurement of cytokines
A vaginal lavage was obtained by injecting two ml of physio-
logical saline solution (NaCl) into the vagina and recovering two
ml of the vaginal fluid, which was centrifuged. The supernatant
was frozen at -80°C. After all samples were obtained, they were
analyzed for the cytokines IL-23, IFN-α, and IFN-β.
The used ELISAs are solid phase sandwich enzyme linked-im-
muno-sorbent assays. A monoclonal antibody specific for IL-23
was coated onto the wells of the provided microtiter plates. Stan-
dards and samples were added to the appropriate wells. A stan-
dard curve was prepared with each assay.
In case of IL-23, an anti-IL-23 biotinylated monoclonal antibody
was added to all wells, except to those reserved for the chromogen
blank. During incubation the antibody bonded to the immobilized
hIL-23. After removing excess second antibody with wash buffer,
streptavidin–HRP was added to each well. The wells were incubated
again and after removing the entire unbound enzymes, a substrate so-
lution was added to produce the colour reaction.
In case of IFN-α and IFN-β the protocol was similar, except
that a HRP-conjugate specific for IFN-α or IFN-β was coated onto
the wells of the provided microtiter stripes. After incubation sub-
strate solution was added to produce the colour reaction.
The absorbance of the standards was plotted on a graph paper
against the standard concentration. The intensity of produced
colour was directly proportional to the cytokine-concentration.
Statistics
All analyses were carried out with the SPSS software. All tests
were two sided using a significance level of 0.05.
Results
The distribution of Candida-subtypes in the VVC group
was as follows: 48 patients (67.6%) tested positive for C.
albicans, in 15 (21.1%) patients C. glabrata was detected,
four patients (5.6%) were positive for C. krusei, and a coin-
fection with C. albicans and C. krusei was found in another
four patients (5.6%) (Table 1).
Women suffering from symptomatic VVC were found to
have significantly lower concentrations of IL-23 in their
vaginal fluid than asymptomatic women of the control
group (p < 0.001) (Figure 1).
The concentration of IFN-α was significantly increased
in the vaginal fluid of patients with VVC compared to the
control group (p < 0.001) (Figure 2). IFN-β was signifi-
cantly decreased in the vaginal fluid of patients of the VVC
group (p = 0.017) (Figure 3). No significant association be-
tween the concentrations of the cytokines in the vaginal
fluid and the Candida subtype was detected by using the
Kruskal-Wallis-test.
Table 1. — Distribution of Candida subtypes in VVC pa-
tients.
Candida subtype Distribution n (%)
Total 71 (100)
C. albicans 48 (67.6)
C. glabrata 15 (21.1)
C. krusei 4 (5.6)
C. albicans + C. krusei 4 (5.6)
C.: Candida.
Figure 1. — Concentration of IL-23 in the vaginal fluid with vul-
vovaginal candidosis (VVC) (n=71) compared to healthy controls
(n=100).
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Discussion
VVC represents a very frequent diagnosis of women af-
fecting all age groups. More than 75% of all women suffer
from at least one episode of VVC per lifetime [2, 5].
Around 10% of these women suffer from recurrent
episodes [4, 5, 24]. VVC presents with pruritus, discharge,
and burning and itching during urination and sexual inter-
course [25]. These unpleasant symptoms do not only rep-
resent stress for the patients themselves, but also can be a
burden for the patients’ relationships. 
In general, the transition from asymptomatic coloniza-
tion to symptomatic VVC is supposed to be associated with
a disruption or loss of the local defence mechanisms [26].
Anton et al. observed that cell-mediated immunity plays an
important role in vaginal bacterial infections [27]. Elevated
concentrations of the anti-inflammatory cytokine IL-4 in
the vaginal fluid of recurrent VVC patients were detected,
which indicates a localized vaginal immunosuppression
[28]. This finding is in accordance with the results of this
analysis. The hypothesis of a compromised local immune
system is confirmed by the finding of decreased IL-23 lev-
els in the vaginal fluid of symptomatic VVC patients. IL-
23 is produced by antigen presenting cells as an unspecific
reaction to an infection with fungi [29, 30]. Especially, C.
albicans seems to induce the release of IL-23 [31] and
thereby the differentiation and proliferation of Th17 [19].
Acosta-Rodriguez et al. observed that C. albicans specific
T-helper memory cells were Th17-lymphocytes [31]. The
Th17 mediated immune response was described to be im-
portant especially on mucous membranes and epithelia
[20, 32]. Wu et al. were able to detect higher levels of IL-
23 mRNA in the vagina of immune-competent mice in-
fected with C. albicans compared to immune-suppressed
mice which supports the findings in the current study [33]. 
Limitation of the present analysis is that a history of prior
VVC in the asymptomatic patients was not assessed. Since
these patients all tested negative for Candida, it remains un-
clear whether they have higher IL-23 levels due to prior
contact to Candida. It is also possible that their IL-23 lev-
els are elevated per se which prevents an infection with
Candida in the first place.
The antiviral function of IFN-α and IFN-β is largely
studied. Type I-IFNs have immune-modulating functions.
On the one hand, they display anti-inflammatory effects as
therapeutic agents against a specific form of multiple scle-
rosis. On the other hand, however, proinflammatory side
effects of an IFN therapy have also been described. The
knowledge about the role of those Type I-IFN in the de-
fence against Candida is less extensive. However, there is
evidence that both IFN are involved in this process [22,
34, 35]. After iv-infusion of Candida, mice lacking the
IFN-α/β receptor died from their inability to control fun-
gal growth, whereas all wild type controls survived. These
data suggest an important role of a IFN-α/β response in
the protection against candida [34].
In this analysis the levels of IFN-α in patients with VVC
were significantly increased. IFN-α can suppress the ex-
pression of IL-17 as well as the differentiation of naive T-
helper cells to Th17 [36]. In a mouse model, reduced
expression of IL-17 in the vaginal fluid was associated
with an exacerbation of the Candida infection [37].
Thereby, the essential role of Th17 in the defence against
Candida would be inhibited. 
Smeekens et al. reasoned from their observations in a
cell culture model that Type I-IFNs most likely IFN-β
modulate the immune reaction induced by C. albicans, di-
recting the defence towards a Th1 response [22]. This is
accordance with the findings of another group who dis-
covered the important role of IFN-β signaling in modu-
lating the host immune response [35]. The in vivo
observation of decreased IFN-β levels in symptomatic
VVC patients confirms these suggestions.
Figure 2. — Concentration of IFN-α in the vaginal fluid of pa-
tients with vulvovaginal candidosis (VVC) (n=71) compared to
healthy controls (n=127).
Figure 3. — Concentration of IFN-β in the vaginal fluid of pa-
tients with vulvovaginal candidosis (VVC) (n=71) compared to
healthy controls (n=92).
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Conclusion
The cytokines IL-23 and IFN-β could be shown to be sig-
nificantly decreased in the vaginal fluid of VVC patients,
suggesting a protective role against VVC. In contrast, IFN-
α which can inhibit Th17, a major factor in the defence
against Candida, was significantly increased.
To the present authors’ knowledge, this is the first analy-
sis in the current literature which could show significant
changes of these cytokines in the vaginal fluid of VVC pa-
tients. These in vivo data support the hypothesis of com-
promised local defence mechanisms against an infection
with Candida in patients suffering from VVC. Supporting
the local immune system may be a benefical future thera-
peutic approach against VVC.
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